Company: LRHC
Filing Date: 2025-09-25
Form Type: S-1
Source: 0001213900-25-091637
Chunk: 47

Company: La Rosa Holdings Corp.
Filing Date: 2025-09-25
Form: S-1
Chunk 47
---
 to the Company, and Curvature Securities, LLC acted as placement agent to the Company in connection with the transactions contemplated
by the Amended Facility Agreement, for which the Company has agreed to pay a cash compensation equal to 1.4985 and 0.1665%, respectively,
of the proceeds of the Company received pursuant to the Facility at the time of the placement of the Advance Shares issued thereunder.

The Company cannot effect any sales under the
Facility (in excess of the $150 million in shares of common stock that were previously approved by the stockholders of the Company) and
the Selling Stockholder will not have any obligation to purchase Advance Shares under the Facility to the extent that after giving effect
to such purchase and sale the aggregate number of Advance Shares issued under the Facility together with any shares of common stock issued
in connection with any other transaction that may be considered part of the same series of transactions, where the number of shares issued
would exceed the number of shares representing 19.99% of the issued and outstanding shares of common stock as of the date of the Facility
(the “Exchange Cap”), unless the Company has obtained stockholder approval as required for issuance of common stock in excess
of the Exchange Cap, in accordance with the applicable rules of Nasdaq. Accordingly, the Company may not have access to the right to sell
the full Commitment Amount (in excess of the $150 million in shares of common stock that were previously approved by the stockholders
of the Company) to the Selling Stockholder under the Facility until such stockholder approval is obtained.

<div align='center'>26</div>

Pursuant to the Amended Facility Agreement, the
Company is required to provide each stockholder entitled to vote at a meeting of stockholders of the Company (the “Stockholder Meeting”),
which shall be promptly called and held not later than sixty (60) days after the Amendment Date (the “Stockholder Meeting Deadline”),
a proxy statement in a form reasonably acceptable to the Investor and counsel, at the expense of the Company to solicit each of the Company’s
stockholders’ affirmative vote at the Stockholder Meeting for approval of the proposal (“Stockholder Proposal”) to authorize
the issuance of all of the Advance Shares issuable under the Facility (in excess of the $150 million in shares of common stock that were
previously approved by the Majority Stockholders on August 6, 2025) in compliance with the rules and regulations of the Nasdaq Capital
Market (such